ArticleCureus2025
The Deadly Masquerade: Unveiling the Fatal Facade of the Great Imitator.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sclerosing cholangitis (SC) is a fibroinflammatory condition that results in the progressive narrowing and destruction of bile ducts. It is generally classified into three distinct types: primary sclerosing cholangitis (PSC), secondary cholangitis, and immunoglobulin G4 (IgG4)-related cholangitis (IRC). IgG4-sclerosing cholangitis (IgG4-SC) is a rare entity characterized by inflammation and strictures within the biliary tree, arising from host-mediated immune responses. This condition represents the biliary manifestation of IgG4-related disease and may mimic other forms of sclerosing cholangiopathy, as well as cholangiocarcinoma. The clinical presentations of these diseases exhibit significant overlap, and diagnosis can be challenging. This case report discusses a 67-year-old male patient diagnosed with isolated IgG4-SC, who was initially suspected of having either cholangiocarcinoma or PSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.